XBiotech IncNASDAQ:XBIT
- LAST PRICE5.3000
- TODAY'S CHANGE (%)0.0400 (0.7605%)
- Bid / Lots5.2400/ 3
- Ask / Lots5.3000/ 1
- Open / Previous Close5.2100 / 5.2600
- Day Range
- 52 Week Range
- Volume82,792
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | XBIT |
|---|---|---|
| 09:32 ET | 2652 | 5.1274 |
| 09:34 ET | 1486 | 5.1525 |
| 09:36 ET | 400 | 5.29 |
| 09:38 ET | 405 | 5.25 |
| 09:41 ET | 100 | 5.25 |
| 09:43 ET | 278 | 5.325 |
| 09:45 ET | 250 | 5.205 |
| 09:48 ET | 150 | 5.264 |
| 09:54 ET | 1045 | 5.11 |
| 09:56 ET | 234 | 5.12 |
| 09:57 ET | 200 | 5.19 |
| 10:10 ET | 360 | 5.1219 |
| 10:12 ET | 2956 | 5.15 |
| 10:14 ET | 499 | 5.15 |
| 10:21 ET | 618 | 5.1361 |
| 10:24 ET | 2079 | 5.11 |
| 10:32 ET | 1550 | 5.15 |
| 10:37 ET | 200 | 5.1 |
| 10:39 ET | 5200 | 5.11 |
| 10:42 ET | 100 | 5.11 |
| 10:44 ET | 4678 | 5.06 |
| 10:46 ET | 500 | 5.0685 |
| 10:50 ET | 100 | 5.07 |
| 10:53 ET | 120 | 5.06 |
| 10:55 ET | 350 | 5.065 |
| 11:00 ET | 1273 | 5.07 |
| 11:04 ET | 300 | 5.06 |
| 11:09 ET | 175 | 5.061 |
| 11:13 ET | 2200 | 5.0662 |
| 11:20 ET | 100 | 5.06 |
| 11:26 ET | 100 | 5.07 |
| 11:27 ET | 530 | 5.06 |
| 11:33 ET | 1363 | 5.075 |
| 11:36 ET | 100 | 5.075 |
| 11:42 ET | 900 | 5.08 |
| 11:54 ET | 100 | 5.1 |
| 11:58 ET | 1600 | 5.14 |
| 12:00 ET | 312 | 5.16 |
| 12:03 ET | 200 | 5.17 |
| 12:05 ET | 3487 | 5.21 |
| 12:12 ET | 1016 | 5.21 |
| 12:14 ET | 300 | 5.19 |
| 12:16 ET | 3457 | 5.11 |
| 12:18 ET | 3116 | 5.2 |
| 12:20 ET | 4251 | 5.28 |
| 12:21 ET | 1261 | 5.28 |
| 12:27 ET | 1096 | 5.32 |
| 12:30 ET | 1320 | 5.4 |
| 12:32 ET | 800 | 5.4 |
| 12:36 ET | 100 | 5.37 |
| 01:10 ET | 593 | 5.24 |
| 01:37 ET | 100 | 5.07 |
| 01:39 ET | 1096 | 5.14 |
| 01:42 ET | 100 | 5.125 |
| 01:55 ET | 850 | 5.19 |
| 01:57 ET | 300 | 5.17 |
| 02:00 ET | 200 | 5.22 |
| 02:11 ET | 200 | 5.26 |
| 02:15 ET | 300 | 5.3 |
Jun 18, 2024
DJ XBiotech Studies Find Potential Treatment for Advanced Pancreatic Cancer, from 12:21PM ET on Tuesday Jun 18, 2024 by Dow Jones
12:21PM ET on Tuesday Jun 18, 2024 by Dow JonesXBiotech Results from Randomized Double-Blinded Phase 1/2 Study Suggest Potential Breakthrough Treatment for Advanced Pancreatic Cancer, from 11:35AM ET on Tuesday Jun 18, 2024 by Dow Jones
11:35AM ET on Tuesday Jun 18, 2024 by Dow JonesXBiotech Results from Randomized Double-Blinded Phase 1/2 Study Suggest Potential Breakthrough Treatment for Advanced Pancreatic Cancer, from 11:35AM ET on Tuesday Jun 18, 2024 by Dow Jones
11:35AM ET on Tuesday Jun 18, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
XBiotech Inc | 160.2M | -5.2x | --- |
X4 Pharmaceuticals Inc | 162.2M | -1.4x | --- |
Regulus Therapeutics Inc | 162.4M | -1.7x | --- |
Achieve Life Sciences Inc | 164.2M | -3.7x | --- |
Outlook Therapeutics Inc | 165.5M | -0.7x | --- |
Compass Therapeutics Inc. | 154.1M | -3.2x | --- |
Company Information
XBiotech Inc. is a biopharmaceutical company that discovers and develops True Human monoclonal antibodies for treating a variety of diseases, such as inflammatory conditions like rheumatology, infectious disease, cardiovascular disease and cancer. The Company's True Human monoclonal antibodies are derived from human donors that mount a natural human immune response. The Company is focused on therapies that block a potent substance, known as interleukin-1 alpha (IL-1a), that mediates a number of pathophysiological processes including tissue breakdown (i.e. synovium, cartilage, bone), paraneoplastic angiogenesis and tumor stroma remodeling, formation of blood clots, malaise, muscle wasting and general inflammation. It has various candidate products including Natrunix. It has a clinical-stage therapeutic for methicillin resistant Staphylococcus aureus (MRSA), and several pre-clinical-stage therapeutics, including an oral delivery antibody therapeutic for colon infection by C. difficile.
Contact Information
- Headquarters
- 5217 WINNEBAGO LANEAUSTIN, TX, United States 78744
- Phone
- 512-386-2900
- Fax
- ---
Executives
- Chairman of the Board, President, Chief Executive Officer, Founder
- John Simard
- Director of Finance
- Angela Hu
- Chief Scientific Officer
- Sushma Shivaswamy
- Lead Independent Director
- Jan-Paul Waldin
- Independent Director
- Peter Libby
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $160.2M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 30.5M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.38 |
EPS | $-1.01 |
Book Value | $7.19 |
P/E Ratio | -5.2x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
